Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

Completed · Not applicable

Conditions studied: Hyperlipidemia

In brief

The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.

Key facts

Study ID

NCT01858376

Run by

Chandan K Sen

People needed

24

Starts

2013-03-01

Expected to finish

2015-01-01

Last updated by the study team

2018-07-27

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients 21-70 years of age
• BMI 25-35

You may not qualify if…

• BMI > 35 OR < 25
• Smokers
• Individuals who are deemed unable to understand the procedures, risks and benefits of the study, i.e. Informed consent will be excluded
• Females who are pregnant as well as individuals who are therapeutically immuno-compromised will also be excluded in order to minimize the risk to such individuals (and fetus) and to decrease statistical variability and to minimize potential of confounders.
• Candidates for inclusion into the study will not include individuals as defined in 45 CFR 46 Subparts B, C and D, nor from any other population which may be considered vulnerable. Pregnant women are excluded to minimize the risk to such individuals (and fetus) and to decrease statistical variability and to minimize potential of confounders.

Where it is running

• The Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.